



AUG 13 1998

Express Mail No. EL 066 225 335 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Ruddy et al.

Serial No.: 08/852,495

Group Art Unit: 1644

Filed: May 7, 1997

Examiner: VanderVegt, F.

For: POLYMORPHISMS IN THE

Attorney Docket No.: 8907-057-999

REGION OF THE HUMAN

(farmaris: 17057 000110)

HEMOCHROMATOSIS GENE

(formerly 17957-000110)

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Assistant Commissioner for Patents Washington, D.C. 20231

Attn: Application Processing Division,

Special Processing and Correspondence Branch

Sir:

Pursuant to the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed March 27, 1998 in connection with above-identified application, Applicants submit herewith: (i) a Substitute Sequence Listing in paper and computer readable form pursuant to 37 C.F.R. §1.821(c) and (e), respectively; (ii) a Verified Statement under 37 C.F.R. § 1.821(f); (iii) a Preliminary Amendment; and (iv) a Petition for Extension of Time under 37 C.F.R. § 1.136(a).

The submission, filed in accordance with 37 C.F.R. §1.821(g), herein does not include new matter.

Respectfully submitted,

Date August 7, 1998

Brian M. Poissant

PENNIE & EDMONDS LLP 1155 Avenue of the Americas

New York, New York 10036-2711 (650) 493-4935

Enclosures

Appli tion No. Vojosc 713

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES
The number decided and or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):
This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). The paper copy contains as required by 37 CFR 1.821(e). The paper copy contains as required by 37 CFR 1.821(e).
Applicant must provide:
An initial or substitute computer readable form (CRF) copy of the "Sequence Listing" An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)
For questions regarding compliance with these requirements, please contact:
For Rules Interpretation, call (703) 308-1123 For CRF submission help, call (703) 308-4212 For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.